Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

Now, his successor has quietly begun to build an elite civilian investigative and special operations force to fight the drug ...

The Company's complementary therapeutic platforms and fully integrated drug development engine provide ... global biopharmaceutical companies. For information about Zymeworks, visit and follow ...

Gain Therapeutics' lead drug candidate, GT-02287 ... whether as a result of new information, future events or otherwise. DOWNLOAD THE DIGITAL EDITION APP ...

Whether or not drug companies create or sponsor social media sites, a world of health information already exists ... might not be fully informed of a poster's motivations or financial involvements.

When it came to my attitude toward weed, I used to be an uneducated asshole. In my early high school years, I would ...

New antibody-drug conjugate (ADC) candidate ... today announced the acceptance of six abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting ...

The purpose of black box warnings is to draw immediate attention to the most serious potential adverse effects of a drug, ...